Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,inventory,accountsPayable,shortTermInvestments,changeToLiabilities,WC,language,region,quoteType,triggerable,quoteSourceName,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,postMarketChangePercent,postMarketTime,postMarketPrice,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,priceHint,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry,address2
t0,GTH,1580132000.0,88871696,49974000,,-115038000,8537000,-112754000,104274000,54549000,-99169000,-99169000,-530000,-6144000,,,,0,92061000,191230000,37512000,-15869000,,-115038000,-112754000,13731000.0,6668072000.0,281569000.0,1593863000.0,152187000.0,1883969000.0,59000.0,38878000.0,-5053129000.0,7805000.0,-21139000.0,26248000.0,1068998000.0,228055000.0,-21139000.0,134265000.0,1676547000.0,33178000.0,224100000.0,25963000.0,28447000.0,,0,1448492000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.0,1.0534263,13.2907 - 13.85,13.29,0.0,0.0,9,9,finmb_645124266,NasdaqGM,Genetron Holdings Limited,CNY,281221,353214,0.0,1630529233,13.43,4.4000006,0.48726475,9.03 - 31.54,-18.11,-0.5741915,9.03,31.54,1621859400,1621859400,1621859400,USD,2,-4.87,-2.7577004,14.852,-1.4219999,-0.09574468,19.65797,-6.22797,-0.31681654,1193546880,15,America/New_York,EDT,-14400000,NGM,0,False,False,13.43,1630526403,0.14000034,13.46,13.85,13.2907,175671,Genetron Holdings Limited,us_market,PREPRE,,,,31.54,9.03,14.85,19.66,281.22k,353.21k,88.87M,,27.26M,16.03%,22.25%,459.62k,1.82,,0.52%,393.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-65.58%,-14.48%,,439.7M,5.72,19.80%,260.22M,-254.61M,-3.07B,,,1.39B,15.15,93.13M,5.81,7.35,,,,Value,102206,Healthcare,799,"Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",Beijing,86 10 5090 7500,China,http://www.genetronhealth.com,86400,Building 11,Diagnostics & Research,"1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District"
t-1,GTH,1680280000.0,88871696,52969000,,-73222000,8537000,-73222000,116308000,84124000,-78222000,-78222000,-6931000,-7347000,,,,0,133944000,212166000,49820000,5000000,,-73222000,-73222000,12265000.0,6657562000.0,277353000.0,1692545000.0,76875000.0,1969898000.0,59000.0,43251000.0,-4940375000.0,,-24701000.0,15362000.0,1375766000.0,228844000.0,-24701000.0,136597000.0,1786065000.0,19609000.0,165918000.0,52539000.0,34071000.0,7603000.0,0,1557221000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.0,1.0534263,13.2907 - 13.85,13.29,0.0,0.0,9,9,finmb_645124266,NasdaqGM,Genetron Holdings Limited,CNY,281221,353214,0.0,1630529233,13.43,4.4000006,0.48726475,9.03 - 31.54,-18.11,-0.5741915,9.03,31.54,1621859400,1621859400,1621859400,USD,2,-4.87,-2.7577004,14.852,-1.4219999,-0.09574468,19.65797,-6.22797,-0.31681654,1193546880,15,America/New_York,EDT,-14400000,NGM,0,False,False,13.43,1630526403,0.14000034,13.46,13.85,13.2907,175671,Genetron Holdings Limited,us_market,PREPRE,,,,31.54,9.03,14.85,19.66,281.22k,353.21k,88.87M,,27.26M,16.03%,22.25%,459.62k,1.82,,0.52%,393.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-65.58%,-14.48%,,439.7M,5.72,19.80%,260.22M,-254.61M,-3.07B,,,1.39B,15.15,93.13M,5.81,7.35,,,,Value,102206,Healthcare,799,"Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",Beijing,86 10 5090 7500,China,http://www.genetronhealth.com,86400,Building 11,Diagnostics & Research,"1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District"
t-2,GTH,1826603000.0,88871696,38556000,,-47998000,8537000,-47998000,92998000,69632000,-58103000,-58103000,-3819000,-1560000,,,,0,111963000,170066000,42331000,10105000,,-47998000,-47998000,9453000.0,6657562000.0,410870000.0,1836056000.0,269708000.0,2246926000.0,59000.0,40494000.0,-4839798000.0,,18233000.0,11975000.0,1635000000.0,364859000.0,18233000.0,130704000.0,2094794000.0,,162794000.0,22972000.0,26595000.0,,0,1729935000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.0,1.0534263,13.2907 - 13.85,13.29,0.0,0.0,9,9,finmb_645124266,NasdaqGM,Genetron Holdings Limited,CNY,281221,353214,0.0,1630529233,13.43,4.4000006,0.48726475,9.03 - 31.54,-18.11,-0.5741915,9.03,31.54,1621859400,1621859400,1621859400,USD,2,-4.87,-2.7577004,14.852,-1.4219999,-0.09574468,19.65797,-6.22797,-0.31681654,1193546880,15,America/New_York,EDT,-14400000,NGM,0,False,False,13.43,1630526403,0.14000034,13.46,13.85,13.2907,175671,Genetron Holdings Limited,us_market,PREPRE,,,,31.54,9.03,14.85,19.66,281.22k,353.21k,88.87M,,27.26M,16.03%,22.25%,459.62k,1.82,,0.52%,393.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-65.58%,-14.48%,,439.7M,5.72,19.80%,260.22M,-254.61M,-3.07B,,,1.39B,15.15,93.13M,5.81,7.35,,,,Value,102206,Healthcare,799,"Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",Beijing,86 10 5090 7500,China,http://www.genetronhealth.com,86400,Building 11,Diagnostics & Research,"1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District"
t-3,GTH,1949120000.0,88871696,29845000,,-2832363000,8537000,-2832363000,88524000,64223000,-52876000,-52876000,-1270000,-827000,,,,0,101735000,154611000,37512000,-2779487000,,-2832363000,-2832363000,6604000.0,6657562000.0,237597000.0,1955724000.0,106935000.0,2193321000.0,59000.0,39698000.0,-4791800000.0,,89903000.0,9841000.0,1843531000.0,212239000.0,92277000.0,112537000.0,2064339000.0,,115196000.0,18192000.0,37940000.0,,0,1852100000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.0,1.0534263,13.2907 - 13.85,13.29,0.0,0.0,9,9,finmb_645124266,NasdaqGM,Genetron Holdings Limited,CNY,281221,353214,0.0,1630529233,13.43,4.4000006,0.48726475,9.03 - 31.54,-18.11,-0.5741915,9.03,31.54,1621859400,1621859400,1621859400,USD,2,-4.87,-2.7577004,14.852,-1.4219999,-0.09574468,19.65797,-6.22797,-0.31681654,1193546880,15,America/New_York,EDT,-14400000,NGM,0,False,False,13.43,1630526403,0.14000034,13.46,13.85,13.2907,175671,Genetron Holdings Limited,us_market,PREPRE,,,,31.54,9.03,14.85,19.66,281.22k,353.21k,88.87M,,27.26M,16.03%,22.25%,459.62k,1.82,,0.52%,393.68k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-65.58%,-14.48%,,439.7M,5.72,19.80%,260.22M,-254.61M,-3.07B,,,1.39B,15.15,93.13M,5.81,7.35,,,,Value,102206,Healthcare,799,"Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.",Beijing,86 10 5090 7500,China,http://www.genetronhealth.com,86400,Building 11,Diagnostics & Research,"1-2 Floors Zone 1, No. 8 Life Science Parkway Changping District"
